Tirzepatide

Tirzepatide –

For Research Purposes Only

What Is Tirzepatide?

Tirzepatide is the active ingredient in the FDA‑approved prescription medication Mounjaro, which is indicated for the treatment of type 2 diabetes under medical supervision. It is also marketed under Zepbound for chronic weight management in specific patient populations.

Mechanism of Action (Scientific Context)

Tirzepatide acts on two incretin hormone receptors:

• GIP receptors – involved in insulin secretion and metabolic regulation

• GLP-1 receptors – associated with glucose control, delayed gastric emptying, and appetite signaling

By activating both pathways, tirzepatide influences multiple metabolic processes simultaneously. Ongoing research continues to evaluate the broader physiological effects of dual incretin receptor agonism.

Important Notice

This page is provided for informational and scientific purposes only.

If referencing tirzepatide in a laboratory context:

• Any non‑approved preparation should be considered for research purposes only.

• Not for human consumption.

• Not for veterinary use.

• Not for therapeutic or diagnostic application outside of approved pharmaceutical products.

Always consult a licensed healthcare provider for medical advice. For regulatory or compliance questions, consult appropriate governing authorities in your jurisdiction.